Menlo Park, CA, USA — Quantapore Inc. today announced that it has closed a Series C financing round, led by China BioPharma Capital I, a venture capital fund advised by TVM Capital Life Science via its Hong Kong based office. Details of the financing were not disclosed.

Quantapore Inc. is developing a novel, single molecule sequencing technology that will significantly reduce the cost of sequencing. Unlike other nanopore approaches, Quantapore utilizes an optical read out which results in lower cost and higher throughput compared to electrical data acquisition. The company’s proprietary sequencing technology will also eliminate other bottlenecks associated with today’s sequencing technologies, namely laborious sample preparation and short read length.

“Quantapore has achieved key milestones in the past 12 months. Sequencing results are very promising and we’re well on our way to a commercial product,” said Quantapore’s CEO Martin Huber. “We are very pleased to have won a new investor which wi